Literature DB >> 9889015

Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS.

S Byers1, T Rozaklis, L K Brumfield, E Ranieri, J J Hopwood.   

Abstract

A combination of anion-exchange chromatography and 30-40% gradient polyacrylamide gel electrophoresis (gradient-PAGE) was used to purify and characterize urinary glycosaminoglycans from various mucopolysaccharidoses (MPS). The urinary glycosaminoglycans from the different MPS displayed distinct patterns on gradient-PAGE and further confirmation of MPS types and subtypes was demonstrated by an electrophoretic shift in the banding pattern after digestion with the appropriate MPS enzyme. Thus each of the MPS accumulates a unique spectrum of glycosaminoglycans with a nonreducing terminal consisting of the substrate specific for the deficient enzyme in that particular MPS disorder. The absolute correlation of the nonreducing terminal structure with a particular MPS and the availability of recombinant lysosomal enzymes provide the means for a rapid and accurate diagnosis of individual MPS. Analysis of tissue glycosaminoglycans in one MPS type (feline MPS VI) indicated a tissue-specific pattern of glycosaminoglycan accumulation. Undegraded glycosaminoglycans had distinct banding patterns on gradient-PAGE and although dermatan sulfate was predominantly excreted in MPS VI urine, some tissues were observed to accumulate predominantly chondroitin sulfate glycosaminoglycans, e.g., bone and kidney. The spectrum of glycosaminoglycans excreted in the urine is therefore most likely a combination of glycosaminoglycans from various tissues. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9889015     DOI: 10.1006/mgme.1998.2761

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  22 in total

1.  Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses.

Authors:  S Tomatsu; M A Gutierrez; T Ishimaru; O M Peña; A M Montaño; H Maeda; S Velez-Castrillon; T Nishioka; A A Fachel; A Cooper; M Thornley; E Wraith; L A Barrera; L S Laybauer; R Giugliani; I V Schwartz; G Schulze Frenking; M Beck; S G Kircher; E Paschke; S Yamaguchi; K Ullrich; K Isogai; Y Suzuki; T Orii; A Noguchi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly.

Authors:  A Hinek; S E Wilson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VI.

Authors:  Min-Ju Chan; Hsuan-Chieh Liao; Michael H Gelb; Chih-Kuang Chuang; Mei-Ying Liu; Hsiao-Jan Chen; Shu-Min Kao; Hsiang-Yu Lin; You-Hsin Huang; Arun Babu Kumar; Naveen Kumar Chennamaneni; Nagendar Pendem; Shuan-Pei Lin; Chuan-Chi Chiang
Journal:  J Pediatr       Date:  2018-11-06       Impact factor: 4.406

4.  Chondroitin sulfate and growth factor signaling in the skeleton: Possible links to MPS VI.

Authors:  Tamara Alliston
Journal:  J Pediatr Rehabil Med       Date:  2010

5.  Caprine mucopolysaccharidosis IIID: a preliminary trial of enzyme replacement therapy.

Authors:  E Downs-Kelly; M Z Jones; J Alroy; K T Cavanagh; B King; R E Lucas; J C Baker; S A Kraemer; J J Hopwood
Journal:  J Mol Neurosci       Date:  2000-12       Impact factor: 3.444

Review 6.  Glycan-based biomarkers for mucopolysaccharidoses.

Authors:  Roger Lawrence; Jillian R Brown; Fred Lorey; Patricia I Dickson; Brett E Crawford; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2013-07-29       Impact factor: 4.797

7.  Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking α-l-iduronidase.

Authors:  Rebecca J Holley; Audrey Deligny; Wei Wei; H Angharad Watson; Milady R Niñonuevo; Anders Dagälv; Julie A Leary; Brian W Bigger; Lena Kjellén; Catherine L R Merry
Journal:  J Biol Chem       Date:  2011-08-26       Impact factor: 5.157

8.  Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.

Authors:  Emma Glamuzina; Emma Fettes; Katie Bainbridge; Victoria Crook; Niamh Finnegan; Lara Abulhoul; Ashok Vellodi
Journal:  J Inherit Metab Dis       Date:  2011-02-16       Impact factor: 4.982

9.  Caprine mucopolysaccharidosis IIID: fetal and neonatal brain and liver glycosaminoglycan and morphological perturbations.

Authors:  Margaret Z Jones; Joseph Alroy; Erinn Downs-Kelly; Rebecca E Lucas; Stacey A Kraemer; Kevin T Cavanagh; Barbara King; John J Hopwood
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 10.  Newborn screening and diagnosis of mucopolysaccharidoses.

Authors:  Shunji Tomatsu; Tadashi Fujii; Masaru Fukushi; Toshihiro Oguma; Tsutomu Shimada; Miho Maeda; Kazuhiro Kida; Yuniko Shibata; Hideyuki Futatsumori; Adriana M Montaño; Robert W Mason; Seiji Yamaguchi; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-21       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.